For Adaptimmune, the termination comes almost exactly one year after another pharma discontinued work with the biotech. In ...
Despite handing over 2.7 billion euros ($2.9 billion) cash to buy out the German biotech in February, the star of the show in ...
At one of the most consequential times for the biotech industry, the head lobbyist at the top trade organization is gone.
This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024.  | Using data from Fierce Biotech's ...
A session at the American Association for Cancer Research annual meeting posed a key question: are cancer vaccines ready for ...
Illumina has received a green light from the European Commission to proceed with unwinding its ownership of Grail, though the ...
Portage Biotech is putting the clamps on existing work to save cash as it prioritizes a hunt for strategic alternatives.  | ...
Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of ...
Researchers have demonstrated that a functional precision medicine approach—combining artificial intelligence, DNA sequencing ...
Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a ...
Following last week’s de novo clearance for the artificial intelligence program, Roche has stepped up to distribute Prenosis’ ...
Few officials at the FDA have the same influence as Richard Pazdur, M.D. | At the inaugural AACR Oncology Industry Partnering ...